{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T06:17:16Z","timestamp":1783664236039,"version":"3.55.0"},"reference-count":59,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T00:00:00Z","timestamp":1783641600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Despite therapeutic advances, inflammatory bowel disease (IBD) remains a lifelong debilitating disorder with substantial burden. The study aimed to investigate disease burden and unmet needs in IBD patients receiving advanced therapies in Greece.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Between October 2023 and January 2024, adult CD and UC patients who were members of Hellenic Society of Crohn\u2019s disease\u2019s and Ulcerative Colitis\u2019 patients (HELLESCC) and receiving advanced therapies completed a structured self-reported questionnaire. The survey collected data on sociodemographic characteristics, smoking status, comorbidities, disease activity, disease characteristics, current medications, and patient-reported outcomes (PROs; Short Inflammatory Bowel Disease Questionnaire [SIBDQ], Work Productivity and Activity Impairment [WPAI], Patient Health Questionnaire-9 [PHQ-9], treatment satisfaction and adherence). Both univariate and multivariate logistic regression analyses were performed to determine associated factors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 287 patients with IBD (201 with CD, 86 with UC) receiving advanced therapies, 57.1% had active disease. Overall, 76.4% reported impaired QoL, 30.3% work productivity loss, and 38.4% activity impairment, while nearly half exhibited moderate-to-severe depressive symptoms. Notably, 39.1% expressed dissatisfaction with their advanced therapy, while 10.9% reported reduced adherence. No significant differences were observed between CD and UC patients across PROs, except for adherence. Higher disease activity was consistently associated with worse QoL, greater work impairment, increased depressive symptoms, and lower treatment satisfaction.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Despite advanced therapies, IBD burden remains substantial among Greek patients. A considerable proportion experience poor QoL, increased work impairment, significant depressive symptoms, and persistent disease activity. Marked treatment dissatisfaction, reported by four out of ten patients, highlights an unmet need for more effective management strategies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1866461","type":"journal-article","created":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T05:39:26Z","timestamp":1783661966000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Persistent disease burden despite advanced therapies in inflammatory bowel disease: a real-world patient-reported survey from Greece"],"prefix":"10.3389","volume":"17","author":[{"given":"Charalampos","family":"Tzanetakos","sequence":"first","affiliation":[{"name":"Health Through Evidence","place":["Athens, Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasiliki-Rafaela","family":"Vakouftsi","sequence":"additional","affiliation":[{"name":"Hellenic Society of Crohn\u2019s disease\u2019s and Ulcerative Colitis\u2019 patients (HELLESCC)","place":["Athens, Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Mavridoglou","sequence":"additional","affiliation":[{"name":"University of Peloponnese","place":["Kalamata, Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andriani","family":"Angelopoulou","sequence":"additional","affiliation":[{"name":"Health Through Evidence","place":["Athens, Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Gourzoulidis","sequence":"additional","affiliation":[{"name":"Health Through Evidence","place":["Athens, Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-022-00634-6","article-title":"Depression and anxiety in inflammatory bowel disease: epidemiology, mechanisms and treatment","volume":"19","author":"Bisgaard","year":"2022","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"100851","DOI":"10.1016\/j.disamonth.2019.02.004","article-title":"A comprehensive review and update on ulcerative colitis","volume":"65","author":"Gajendran","year":"2019","journal-title":"Disease-a-Month DM"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.5009\/gnl210118","article-title":"Long-term disease course of Crohn's disease: changes in disease location, phenotype, activities, and predictive factors","volume":"16","author":"Cho","year":"2022","journal-title":"Gut Liver"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.disamonth.2023.101672","article-title":"Factors influencing the quality of life in inflammatory bowel disease: a comprehensive review","volume":"70","author":"Khan","year":"2024","journal-title":"Disease-a-Month"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.coph.2025.102577","article-title":"Targeting the unmet needs in IBD: emerging therapies beyond biologics and small molecules","volume":"85","author":"Fanizzi","year":"2025","journal-title":"Curr Opin Pharmacol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izz001","article-title":"Real-world pattern of biologic use in patients with inflammatory bowel disease: treatment persistence, switching, and importance of concurrent immunosuppressive therapy","volume":"25","author":"Chen","year":"2019","journal-title":"Inflammatory Bowel Dis"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-023-02605-y","article-title":"Unmet needs in real-world advanced therapy-na\u00efve and -experienced patients with moderately to severely active ulcerative colitis in the United States","volume":"40","author":"Afzali","year":"2023","journal-title":"Adv Ther"},{"key":"B8","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1186\/s12955-020-01489-8","article-title":"Assessment of patient-centered outcomes (PROs) in inflammatory bowel disease (IBD): a multicenter survey preceding a cross-disciplinary (functional) consensus","volume":"18","author":"Yan","year":"2020","journal-title":"Health Qual Life Outcomes"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1093\/crocol\/otad006","article-title":"The real-world global use of patient-reported outcomes for the care of patients with inflammatory bowel disease","volume":"5","author":"Horrigan","year":"2023","journal-title":"Crohn's Colitis 360"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.614653","article-title":"Patient reported outcomes in chronic inflammatory diseases: current state, limitations and perspectives","volume":"12","author":"Tran","year":"2021","journal-title":"Front Immunol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1016\/j.cgh.2014.02.016","article-title":"Patient-reported outcomes as primary end points in clinical trials of inflammatory bowel disease","volume":"12","author":"Williet","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1186\/s12955-017-0753-2","article-title":"Inflammatory bowel disease-specific health-related quality of life instruments: a systematic review of measurement properties","volume":"15","author":"Chen","year":"2017","journal-title":"Health Qual Life Outcomes"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1093\/jcag\/gwaa014","article-title":"Factors associated with poor quality of life in a Canadian cohort of patients with inflammatory bowel disease: a cross-sectional study","volume":"4","author":"Nazarian","year":"2021","journal-title":"J Can Assoc Gastroenterol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1177\/2050640619852532","article-title":"Health-related quality of life in inflammatory bowel disease in a Danish population-based inception cohort","volume":"7","author":"Christiansen","year":"2019","journal-title":"United Eur Gastroenterol J"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjw145","article-title":"Patient-reported outcomes in a French nationwide survey of inflammatory bowel disease patients","volume":"11","author":"Williet","year":"2017","journal-title":"J Crohn's Colitis"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1097\/00004836-199201000-00005","article-title":"The Short Inflammatory Bowel Disease Questionnaire: a quality of life instrument for community physicians managing inflammatory bowel disease","volume":"91","author":"Irvine","year":"1996","journal-title":"Am J Gastroenterol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.2165\/00019053-199304050-00006","article-title":"The validity and reproducibility of a work productivity and activity impairment instrument","volume":"4","author":"Reilly","year":"1993","journal-title":"PharmacoEconomics"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.gastha.2022.07.003","article-title":"Poor patient-reported outcomes and impaired work productivity in patients with inflammatory bowel disease in remission","volume":"1","author":"Cross","year":"2022","journal-title":"Gastro Hep Adv"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjae057","article-title":"Work productivity impairment in persons with inflammatory bowel diseases: a systematic review and meta-analysis","volume":"18","author":"Youssef","year":"2024","journal-title":"J Crohn's Colitis"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/6496727","article-title":"Prevalence of anxiety and depression in patients with inflammatory bowel disease","volume":"2017","author":"Byrne","year":"2017","journal-title":"Can J Gastroenterol Hepatol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1046\/j.1525-1497.2001.016009606.x","article-title":"The PHQ-9: validity of a brief depression severity measure","volume":"16","author":"Kroenke","year":"2001","journal-title":"J Gen Internal Med"},{"key":"B22","doi-asserted-by":"publisher","first-page":"17562848251325190","DOI":"10.1177\/17562848251325190","article-title":"Unmet needs in adult patients with ulcerative colitis in Spain: a real-world Adelphi Disease Specific Programme study","volume":"18","author":"Mar\u00edn-Jim\u00e9nez","year":"2025"},{"key":"B23","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1186\/s13690-025-01632-1","article-title":"Unmet health-related needs in patients with Crohn\u2019s disease in Belgium: a mixed-methods study","volume":"83","author":"Sch\u00f6nborn","year":"2025","journal-title":"Arch Public Health"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1093\/crocol\/otae074","article-title":"Real-world impact of uncontrolled symptoms and suboptimal treatment response in patients with Crohn\u2019s disease in the United States and Europe","volume":"7","author":"Kershaw","year":"2024","journal-title":"Crohn's Colitis 360"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3390\/medsci13030117","article-title":"Disease burden and unmet medical needs in patients with ulcerative colitis in Greece: a cross-sectional patient survey","volume":"13","author":"Gourzoulidis","year":"2025","journal-title":"Med Sci (Basel Switzerland)"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.20524\/aog.2025.1013","article-title":"Disease burden and unmet medical need in patients with Crohn's disease in Greece: a cross-sectional patient survey","volume":"38","author":"Tzanetakos","year":"2025","journal-title":"Ann Gastroenterol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.20524\/aog.2022.0708","article-title":"The ulcerative colitis narrative Greece survey: patients' and physicians' perspective on quality of life and disease management","volume":"35","author":"Viazis","year":"2022","journal-title":"Ann Gastroenterol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/6138105","article-title":"Disability in patients with inflammatory bowel disease: correlations with quality of life and patient's characteristics","volume":"2017","author":"Argyriou","year":"2017","journal-title":"Can J Gastroenterol Hepatol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1136\/gut.43.1.29","article-title":"A simple clinical colitis activity index","volume":"43","author":"Walmsley","year":"1998","journal-title":"Gut"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.crohns.2013.09.010","article-title":"Comparing disease activity indices in ulcerative colitis","volume":"8","author":"Walsh","year":"2014","journal-title":"J Crohn's Colitis"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1080\/00365520310000654","article-title":"Defining relapse of ulcerative colitis using a symptom-based activity index","volume":"38","author":"Jowett","year":"2003","journal-title":"Scandinavian J Gastroenterol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1097\/01.MIB.0000215091.77492.2a","article-title":"Predicting the Crohn's disease activity index from the Harvey-Bradshaw Index","volume":"12","author":"Best","year":"2006","journal-title":"Inflammatory Bowel Dis"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjv113","article-title":"High rates of smoking especially in female Crohn\u2019s disease patients and low use of supportive measures to achieve smoking cessation\u2014data from the Swiss IBD Cohort Study","volume":"9","author":"Biedermann","year":"2015","journal-title":"J Crohn's Colitis"},{"key":"B34","doi-asserted-by":"publisher","first-page":"45","DOI":"10.5217\/ir.2019.00135","article-title":"Quality of life in inflammatory bowel diseases: it is not all about the bowel","volume":"19","author":"Keller","year":"2021","journal-title":"Intestinal Res"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjac015","article-title":"Smoking behaviour changes after diagnosis of inflammatory bowel disease and risk of all-cause mortality","volume":"16","author":"Hua","year":"2022","journal-title":"J Crohn's Colitis"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjad212.1389","article-title":"N17 exploration of medication non-adherence in inflammatory bowel disease patients: a systematic review","volume":"18","author":"King","year":"2024","journal-title":"J Crohn's Colitis"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.17235\/reed.2017.5137\/2017","article-title":"Assessing medication adherence in inflammatory bowel diseases. A comparison between a self-administered scale and a pharmacy refill index","volume":"109","author":"de Castro","year":"2017","journal-title":"Rev Espanola Enfermedades Digestivas"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3238\/arztebl.2009.0335","article-title":"Confidence interval or p-value?: part 4 of a series on evaluation of scientific publications","volume":"106","author":"du Prel","year":"2009","journal-title":"Deutsches Arzteblatt Int"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00061-2","article-title":"Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies","volume":"401","author":"Sandborn","year":"2023","journal-title":"Lancet"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00581-5","article-title":"Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials","volume":"399","author":"Danese","year":"2022","journal-title":"Lancet"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2025.10.128","article-title":"Long-term outcomes of biologic therapy in IBD: a meta-analysis of real-world and randomized data","volume":"170","author":"Shah-Riar","year":"2026","journal-title":"Gastroenterology"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.97297","article-title":"Impact of inflammatory bowel disease on quality of life and work productivity in patients under treatment","volume":"17","author":"Kafalis","year":"2025","journal-title":"Cureus"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1111\/apt.17058","article-title":"The disease severity index for inflammatory bowel disease is associated with psychological symptoms and quality of life, and predicts a more complicated disease course","volume":"56","author":"Swaminathan","year":"2022","journal-title":"Alimentary Pharmacol Ther"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1002\/ueg2.12668","article-title":"Impact of pain, fatigue and bowel incontinence on the quality of life of people living with inflammatory bowel disease: a UK cross-sectional survey","volume":"13","author":"Roukas","year":"2025"},{"key":"B45","article-title":"Inflammatory bowel disease: Greek patients' perspective on quality of life, information on the disease, work productivity and family support","volume":"26","author":"Viazis","year":"2013","journal-title":"Ann Gastroenterol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.3390\/medicina59040682","article-title":"Mental illnesses in inflammatory bowel diseases: mens sana in corpore sano","volume":"59","author":"Bartocci","year":"2023","journal-title":"Med (Kaunas Lithuania)"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.28502","article-title":"Quality of life in patients with inflammatory bowel disease: importance of psychological symptoms","volume":"14","author":"Mitropoulou","year":"2022","journal-title":"Cureus"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph20136255","article-title":"Depressive and anxiety disorders in patients with inflammatory bowel diseases: are there any gender differences","volume":"20","author":"Fracas","year":"2023","journal-title":"Int J Environ Res Public Health"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-023-01888-3","article-title":"The effect of biological treatment on fatigue in inflammatory bowel disease: a systematic review and meta-analysis","volume":"83","author":"Skjellerudsveen","year":"2023","journal-title":"Drugs"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.3390\/life13081692","article-title":"The role of chronic fatigue in patients with Crohn's disease","volume":"13","author":"W\u0142odarczyk","year":"2023","journal-title":"Life (Basel Switzerland)"},{"key":"B51","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.3390\/medicina61091512","article-title":"Treatment adherence in inflammatory bowel disease: The role of demographic, clinical, and psychosocial factors","volume":"61","author":"Stroie","year":"2025"},{"key":"B52","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s11096-025-02061-4","article-title":"Adherence to biologics in patients with inflammatory bowel disease: a systematic review and meta-analysis","volume":"48","author":"Pan","year":"2026","journal-title":"Int J Clin Pharm"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.3390\/jcm8081171","article-title":"The combination of patient-reported clinical symptoms and an endoscopic score correlates well with health-related quality of life in patients with ulcerative colitis","volume":"8","author":"Aniwan","year":"2019","journal-title":"J Clin Med"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1111\/imj.13937","article-title":"Examination of the relationship between disease activity and patient-reported outcome measures in an inflammatory bowel disease cohort","volume":"48","author":"Jackson","year":"2018","journal-title":"Internal Med J"},{"key":"B55","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1186\/s12876-022-02578-2","article-title":"Multimorbidity among inflammatory bowel disease patients in a tertiary care center: a retrospective study","volume":"22","author":"Mosli","year":"2022","journal-title":"BMC Gastroenterol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1007\/s12178-011-9085-8","article-title":"Inflammatory bowel disease associated arthropathy","volume":"4","author":"Arvikar","year":"2011","journal-title":"Curr Rev Musculoskeletal Med"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1093\/crocol\/otac023","article-title":"Work-related productivity loss and associated indirect costs in patients with Crohn's disease or ulcerative colitis in the United States","volume":"4","author":"Ding","year":"2022","journal-title":"Crohn's Colitis 360"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v25.i38.5862","article-title":"Quality of life, work productivity impairment and healthcare resources in inflammatory bowel diseases in Brazil","volume":"25","author":"Parra","year":"2019","journal-title":"World J Gastroenterol"},{"key":"B59","doi-asserted-by":"publisher","first-page":"S420","DOI":"10.1016\/j.jval.2022.09.2087","article-title":"PCR152 underutilization of a validated treatment satisfaction instrument in inflammatory bowel disease","volume":"25","author":"Hubscher","year":"2022","journal-title":"Value Health"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1866461\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T05:39:27Z","timestamp":1783661967000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1866461\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,10]]},"references-count":59,"alternative-id":["10.3389\/fimmu.2026.1866461"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1866461","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,10]]},"article-number":"1866461"}}